Jason Hurt, Founder & CEO of Theragnostic Insights
Send us a textIn this episode, we are joined by Dr. Jason Hurt, a clinician-scientist and entrepreneur with extensive experience in radiopharmaceutical development, clinical trial strategy, and oncology drug development. In March 2025, Dr. Hurt founded Theragnostic Insights, a consulting and strategic advisory firm focused on advancing theranostic solutions and radioligand therapies—pioneering approaches that are shaping the future of cancer treatment.
--------
25:02
--------
25:02
Martin Schiller, Founder & CEO of Heligenics Inc
Send us a text In this episode, we sit down with Dr. Martin R. Schiller, Prabhu Endowed Professor at UNLV, Founding Director of the Nevada Institute of Personalized Medicine, and founder of Heligenics Inc. Dr. Schiller shares his journey from academia to entrepreneurship, the breakthroughs behind the GigaAssay technology, and how personalized medicine is shaping the future of healthcare. Tune in to learn how cutting-edge research in genomics and biotechnology is being translated into real-world therapies and diagnostics.
--------
32:38
--------
32:38
Ross Youngs, Founder & CEO of Biosortia
Send us a textToday’s guest is Ross O. Youngs, Founder and CEO, with over 35 years of experience inventing products, technologies, and processes across multiple industries. He holds more than 75 patents worldwide and is driven by a passion for creating innovations that are better, faster, and more cost-effective. His recent accomplishments include winning an R&D 100 Award for his work in biopolymer technologies. In 2009, his company Biosortia was awarded a $6 million ARPA-E grant from the U.S. Department of Energy for its algal harvesting technology—work that paved the way for Biosortia’s cutting-edge drug discovery platform. Throughout his career, Ross has been widely recognized for his entrepreneurial leadership, including being named Ernst & Young Ohio Entrepreneur of the Year and receiving the U.S. Small Business Administration’s “Business Person of the Year” award, presented to him by then-Vice President Al Gore.
--------
29:44
--------
29:44
Gianluca Fontana, CEO & Co-Founder of Prova Health
Send us a textToday we’re joined by Gianluca Fontana, CEO and Co-Founder of Prova Health—the London-based advisory firm helping digital health and life sciences innovators prove their value with rock-solid clinical and economic evidence. With a background as a McKinsey consultant and Deputy Director at Imperial College London’s Institute of Global Health Innovation, Gianluca has led billion-pound research programs like the NHS Digital Academy and the REACT COVID-19 study. His published work on digital health evaluation has been cited hundreds of times, and through Prova Health he now works with global pharma and AI-medtech scale-ups to accelerate evidence generation and build lasting capabilities. Fluent in four languages and trained in both economics and marketing at Bocconi University, Gianluca brings a rare mix of scientific rigor and commercial insight—making him an invaluable voice in the race to deliver safer, smarter healthcare at scale.
--------
36:37
--------
36:37
Justin Chickles, CEO & Co-Founder of Glycyx Therapeutics
Send us a textCould opioids be silently undermining cancer immunotherapy?This week, Justin Chickles — CEO and co-founder of Glycyx Therapeutics — explains how his team is tackling this overlooked challenge with axelopran, a breakthrough therapy now advancing to Phase 2 trials.From his early career at Johnson & Johnson to leading multiple startups, Justin offers a rare, insider’s perspective on driving biotech innovation from concept to clinic. If you’re interested in cutting-edge oncology, translational science, and biotech entrepreneurship, you won’t want to miss this episode.
Acerca de Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere
Hosted by bioaccess® CEO, Julio G. Martinez-Clark, the Global Trial Accelerators™ podcast delivers actionable insights for Medtech, Biopharma, and Radiopharma innovators battling lengthy timelines and costly delays. Each episode features candid conversations with clinical trial pioneers, regulatory strategists, and startup founders who’ve slashed 6–12 months off approvals by leveraging emerging regions like Latin America, Eastern Europe, and Australia.What You’ll Learn:Speed Secrets: How to secure ethics approval in 4–6 weeks (vs. 6+ months in US/EU) using harmonized pathways like MINSA (Panama), ALIMS (Serbia), and Australia’s CTN.Cost-to-Speed Hacks: Operational strategies to reduce trial budgets by 30% while maintaining FDA/EMA compliance.Global Patient Access: Leverage treatment-naive populations in cardiology, rare diseases, and advanced therapies across 50+ pre-vetted sites.Why Listen?Actionable Playbooks: Reverse-engineer success stories from startups that enrolled cohorts 50% faster and secured Series B funding 12–18 months early.Regulatory Intel: Stay ahead of shifting LATAM, Balkans, and APAC guidelines with on-the-ground experts.Future-Proof Insights: Explore decentralized trials, AI-driven recruitment, and post-trial commercialization in $1B+ markets.“bioaccess®’s Serbia site activated in 8 weeks-9 months faster than our EU delay. This podcast is why we partnered with them.”– Digital Health Startup CEONew episodes drop weekly. Subscribe to unlock your shortcut to global trial velocity.Brought to you by bioaccess® – Turning “anywhere” into accelerated FDA/EMA submissions since 2010.
Escucha Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere, Dinstinto y muchos más podcasts de todo el mundo con la aplicación de radio.net
Colombia